New Laser Therapy Treats Prostate Cancer Without Side Effects

Men with prostate cancer have long faced an impossible choice: treat the cancer aggressively and suffer from incontinence and erectile dysfunction, or risk the disease spreading. A new laser therapy is finally changing that equation.

The ProFocal device just completed its first major clinical trial with 100 patients, and the results offer genuine hope. At three months after treatment, 84% of participants showed no clinically significant cancer on their biopsies.

What makes this breakthrough special isn't just the cancer control. Traditional treatments like radical prostatectomy and radiotherapy work well against cancer but devastate patients' daily lives with very high rates of incontinence and erectile dysfunction that can last for years.

ProFocal takes a different approach called focal therapy. Instead of treating the entire prostate gland, the cooled laser device targets only the cancerous tissue while sparing healthy areas. Think of it as precision medicine at its finest.

Dr. Jonathan Kam from Nepean Hospital in Australia led the trial and sees this as a turning point. "Patients can have their prostate cancer treated with a very low risk of suffering the side effects associated with traditional prostate cancer treatments," he explained.

The safety profile sets ProFocal apart from other focal therapy devices. While delivering similar cancer outcomes, it showed remarkably low rates of incontinence compared to whole-prostate treatments.

This matters for millions of men. Prostate cancer remains one of the most common cancers in men, and the fear of treatment side effects sometimes leads patients to delay care or choose less aggressive options than they need.

Why This Inspires

Medical innovation works best when it remembers that treating disease means caring for whole people, not just eliminating cancer cells. ProFocal represents years of engineering focused on a simple question: how can we fight cancer without destroying quality of life?

The device proves that minimally invasive doesn't mean less effective. For decades, men accepted terrible side effects as the price of survival, but this technology shows we can aim higher.

The trial results were published in BJU International, and the treatment is moving through approval processes. Thousands of men are already asking their doctors about focal therapy options as word spreads through patient communities.

For newly diagnosed patients facing that impossible choice, the future just got brighter.